Skip to main content
Premium Trial:

Request an Annual Quote

RealSeq Biosciences Raises $1.5M in Oversubscribed Seed Financing Round

NEW YORK – RNA fragmentomics company RealSeq Biosciences announced on Thursday that it has raised $1.5 million in an oversubscribed seed financing round. 

The round was co-led by Tech Coast Angels Los Angeles and Tech Coast Angels Orange County. Other investors include Chemical Angel Network, Angel Star Ventures, members of the Berkeley Angel Network, Virtual Angels Network, MEDA Angels, and TiE SoCal Angels. 

The Santa Cruz, California-based company said it will use the funding to validate its molecular RiboMarker platform, further develop its laboratory-developed test to diagnose fungal disease Valley Fever, and expand its research and development and business operations, the . The firm is initially focusing on fungal diseases where early treatment is essential for patient outcomes, it added.

"This new funding provides critical support to our technology development and launch objectives over the next 24 months," RealSeq CEO Sergio Barberan-Soler said in a statement. 

John Grant, a member of Tech Coast Angels Los Angeles, will join the RealSeq board of directors as part of the funding. 

RealSeq develops technologies based on RNA fragmentomics, small RNA analysis, next-generation sequencing-based research tools, and biomarkers.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.